Overall, these suggest that the MDM2 gene can not only become amplified, which is a hallmark of well-differentiated liposarcoma/atypical lipomatous tumor, but also can be targeted treatment outcomes for sarcoma and other cancers. This evidence concerns the gene MDM2 and sarcoma.